Stage III MMRp/MSS Resectable Colon Cancer
ANABAnaptyBio IncCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Jemperli/Dostarlimab (PD-1 Antagonist) in Stage III MMRp/MSS Resectable Colon Cancer. The expected timing is based on the latest available company guidance and may change.
11/04/25:- AZUR-4 Ph2 colon cancer trial testing dostarlimab plus chemotherapy versus standard care; data timing TBA. 03/03/26:- AZUR-4 Ph2 MMRp/MSS stage III colon cancer trial ongoing; topline data expected in Q4 2026. 05/12/26:- AZUR-4 Phase 2 colon cancer data expectation reiterated for Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.